Advertisement

Topics

Latest "Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal" News Stories

10:43 EST 11th December 2018 | BioPortfolio

Here are the most relevant search results for "Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal" found in our extensive news archives from over 250 global news sources.

More Information about Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal for you to read. Along with our medical data and news we also list Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal Companies for you to search.

Showing "Tumor Microenvironment Confers MTOR Inhibitor Resistance Invasive Intestinal" News Articles 1–25 of 8,400+

Tuesday 11th December 2018

Immunotherapy Offers Hope to Neurofibromatosis Type 1 Brain Tumor Patients

Although brain tumors have largely remained resistant to immunotherapy, a new study has shown that a slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 (NF1) may be vulnerable to that treatment approach. The findings (“The molecular landscape of glioma in patients with Neurofibromatosis 1”), made by an international consortium led by researchers […] The pos...


PharmaCyte Discusses Pancreatic Cancer Clinical Trial with Medpace’s Medical Monitor Dr. Lyon Gleich

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released an interview with Lyon Gleich, M.D., of Medpace, a global full-service clinical contract research organization (CRO). Dr. Gleich serves as the Med...

Sareum Holdings Plc SAR Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummarySareum Holdings Plc Sareum is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library SKIL. The company delivers drug candidates for licensing to biotechnology and pharmaceutical com...


Sirtex Medical Ltd SRX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummarySirtex Medical Ltd Sirtex Medical is a medical device company that develops and markets device for the treatment of liver cancer. The company's sirspheres microsphere is a medical device, which is used in selective internal radiation therapy for liver tumors. Its product Y90 resin microspheres reside in the small blood vessels of the tumor where they destroy it from the inside while saving ...

Avid Bioservices Inc CDMO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryAvid Bioservices Inc Avid Bioservices, formerly Peregrine Pharmaceuticals Inc, is a biopharmaceutical company that develops, manufactures and markets monoclonal antibodies for the treatment and diagnosis of cancer. The company's products include Bavituximab, PGN650 and Cotara. Its Bavituximab is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipi...

Kazia Therapeutics Ltd KZA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryKazia Therapeutics Limited Kazia Therapeutics, is a clinical stage biotechnology company which focuses on the discovery and development of anticancer drugs. It develops its products based on three drug technology platforms, phosphoinositide 3kinase PI3K inhibitors, antitropomyosins ATM and superbenzopyrans SBP. ATM drugs that target the cancer cell cytoskeleton are being developed for the t...

Propanc Biopharma Inc PPCB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryPropanc Biopharma Inc Propanc, formerly Propanc Health Group Corp, is a clinical stage biopharmaceutical company, which manufactures products for the treat of metastatic, pancreatic, ovarian and colorectal cancers. The company's lead product candidate, PRP, a onceaday intravenous formulation of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, helps block the recurrence of tumor ...

Rezolute Inc RZLT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryRezolute Inc Rezolute formerly known as AntriaBio Inc, is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for the treatment of metabolic and orphan diseases. Its pipeline product portfolio includes AB101, a microsphere formulation of PEGylated human recombinant insulin for use in type 1 and type 2 diabetes for the control of hyperglyce...

Precision Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryPrecision Biologics Inc PBI, a subsidiary of NantWorks LLC, is a clinical stage biotechnology company. The company offers cancer vaccines, antigens and antibodies, pipelines, diagnostics, therapeutics, clinical trials, tumor specific antigens, companion diagnostic programs, and diagnostic biomarker for pancreatic and colorectal cancers. It provides services such as development of pharmaceut...

Asuragen Inc Medical Equipment Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryAsuragen Inc Asuragen is an oncology molecular diagnostic company that provides laboratory medicine solutions. The company offers products such as amplidex, quantidex, and custom reagents. It provides custom and companion diagnostic services, which include commercialization, product approval, development, discovery, partnered research and development and tumor bank programs. Asuragen's cust...

National Institute for Health and Care Excellence (NICE) Issues New Guidelines for COPD, Recommending Severe Patients be Evaluated for Bronchoscopic Lung Volume Reduction

NICE makes a “strong” recommendation that patients with severe COPD be referred for evaluation for bronchoscopic lung volume reduction, including the Zephyr® Endobronchial Valve System. NICE has broadened the criteria for evaluation and a new group of people for whom lung volume reduction surgery was unsuitable may now ...

Anthem Blue Cross Blue Shield Joins List of 60 Commercial Plans Covering Avedro’s FDA-Approved Corneal Cross-Linking Procedure

Cross-linking now covered by the top five largest commercial insurance companies Avedro, Inc., a leading commercial-stage ophthalmic medical technology company and a global leader in corneal remodeling, today announced that Anthem, the largest member of the Blue Cross Blue Shield Association, has issued a positive coverage policy for Avedro’s ...

Versant Ventures Launches Black Diamond Therapeutics

Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine Black Diamond Therapeutics, a biotechnology company developing a new type of precision medicine for cancer, came out of stealth mode today with a $20 million Series A financing exclusively from founding investor Versant Ventures. Black Diamond is the first company ...

Analytics 4 Life® and Actelion Enter Research Agreement to Develop New Diagnostics for Pulmonary Hypertension

Research endeavor marks a clinical research expansion of the CorVista® platform Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, and Actelion Pharmaceuticals Ltd., today announced a collaborative

SPINE/RX™ Brings Modern Spine Surgery Solutions to Hoboken, New Jersey

Renowned Spine Surgeon Dr. James W. Dwyer Provides Advanced Surgical Care for Neck and Back Pain HOBOKEN, N.J. (PRWEB) December 11, 2018 SPINE/RX, a modern spine surgery practice, has opened its doors to the North Jersey area to provide relief for those suffering from neck, back, and other spine-related pain. Led by one of New Jersey’s top spine surgeons, Dr. James W. Dwyer, SPINE/RX offers pat...

Aro Biotherapeutics Raises $13 Million and Establishes Leadership Team to Develop Next Generation of Protein Therapeutics

- Aro is focused on the research and development of Centyrins to transform the treatment of cancer and other serious diseases - Aro Biotherapeutics, a newly established biotechnology company, has raised $13 million in start-up investment to develop and commercialize Centyrins, an innovative next generation protein drug platform. Co-founded by Sue Dillo...

Noxxon to present data from Nox─A12/Keytruda combo trial at Esmo Immuno─Oncology congress

Noxxon Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumour microenvironment (TME), announced the details of its participation at the ESMO Immuno─Oncology

Tailored treatment for acute myeloid leukaemia

The screening of leukaemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for AML... The post Tailored treatment for acute myeloid leukaemia appeared first on European Pharmaceutical Review.

AMRA Receives U.S. FDA Clearance for AMRA® Profiler, a Magnetic Resonance Diagnostic Software Application Enabling Non-Invasive Evaluation of Body Composition

Clinical professionals can now utilize a 6-minute MRI scan to access best-in-class measurements of body fat and muscle, alongside high-quality medical images, to assist in patient diagnosis AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now...

Ron Klain Joins BrainScope Board of Directors

Brings Extensive Experience in Industry, Government and Public Health BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that Ron Klain, Executive Vice President and General Counsel of the investment firm Revolution, has joined BrainScope’s Board of Directors. ...

Wound Care: Nexodyn® AOS Comes to Fruition in Slovakia

Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based product for acute and chronic wound management, is now available in Slovakia, promoted and commercialized by the pharmaceutical companies Evopharm and Sanomed, pursuant to an exclusive partnership with the Swiss pharma company APR Applied Pharma Research s.a. (“APR”). After Slovakia, in ...

TROUBLE BIPOLAIRE : L’alimentation et le poids influent sur la réponse au traitement

On sait déjà que l'alimentation peut avoir des effets sur l’humeur, via le microbiote intestinal, cette étude montre que le régime alimentaire comme le poids peuvent affecter la réponse au traitement du trouble bipolaire. Présentée au Congrès 2018 du Collège européen de neuropsychopharmacologie, cette recherche suggère ainsi que les patients atteints de ces « sautes d’humeur...

BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, The post BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers appeared first on Pharmaceutical Business review.

The Genome of Giant Tortoise "Lonesome George" Provides Clues to Longevity and Disease Resistance http://dlvr.it/QtKzpY pic.twitter.com/lotigxnG3Q

The Genome of Giant Tortoise "Lonesome George" Provides Clues to Longevity and Disease Resistance http://dlvr.it/QtKzpY  pic.twitter.com/lotigxnG3Q

Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec® OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market a...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks